CANCER CONTROL

TJU-08D.213: Jefferson Pancreas Tumor Registry (JPTR)

The purpose of this research study is to collect information to determine if pancreas tumors and related conditions tend to occur more frequently in families with a history of the disease and to determine environmental and occupational risk factors to which patients may be exposed.

Learn more about the TJU-08D.213 trial by calling the Reading Hospital Protocol Office at 484-628-8193.

COVID-19

NCI COVID-19: NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study

The purpose of this study is to collect blood samples, medical information, and copies of medical images from patients who are being treated for cancer and have COVID-19. We will use these samples, information, and images to answer questions about how cancer affects COVID-19 and how COVID-19 affects cancer treatment outcomes.

Learn more about the NCI COVID-19 in Cancer Patients, NCCAPS Study or contact the Pottstown Hospital Clinical Research Office at 610-327-7544 or the Reading Hospital Protocol Office at 484-628-8193.

REGISTRY

RH-007-19: Genomic Profiling of Lymphoma in Residents of Berks County

The purpose of this study is to analyze genomic assays of a broad range of lymphoma tumor subtypes obtained from an ethnically and racially diverse sample population of Berks County, Pennsylvania.

Learn more about the RH-007-19 registry by contacting the Reading Hospital Protocol Office at 484-628-8193.

TJU-17C.072 Ironman: Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN)

The purpose of this study is to learn more about the prostate cancer and to describe the use of different therapies for advanced prostate cancer internationally; to describe specific treatment patterns and whether they are associated with differences in outcomes such as hospitalizations; to identify associations between treatment sequences or combinations and overall survival; to define the patient experience of men with advanced prostate cancer and identify unmet needs in their treatment; to identify clinical and molecular disease subtypes that may predict for a reduction in cancer from individual treatments, combinations, or sequences.

Learn more about the TJU-17C.072 Ironman registry or contact the Reading Hospital Protocol Office at 484-628-8193.

TJU-17F.394 Yang: A population-based approach to single CTC analysis in metastatic breast cancer outcome

We hope to use this information to find out the useful markers and apply them in the clinical setting in the future to improve the prognosis (outcome) of breast cancer patients. These analyses will not be done in real-time, so the results of these markers will not affect or influence the patient’s current course of treatment. But participation in this research will be very helpful to understand better how to help other people with the same disease.

Learn more about the TJU-17F.394 registry or contact the Reading Hospital Protocol Office at 484-628-8193.

RSSearch Registry: The RSSearch® Patient Registry is an international multi-year database designed to track utilization of all available stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) systems, treatment practices and outcomes to help determine, over time, the most effective use of the these systems in management of patients with life threatening tumors and other diseases.

Learn more by contacting the Pottstown Hospital Clinical Research Office at 610-327-7544.

RISK ASSESSMENT

CITY OF HOPE-RA-COH 96144: Molecular genetics studies of cancer patients and their relatives

The purpose of this study is to investigate genetic, biologic, and behavioral factors that may contribute to the development of specific cancers and to study how these factors affect the outcome of the disease.

Learn more about the City of Hope-RA-COH 96144 trial by calling the Reading Hospital Protocol Office at 484-628-8193.

TRANSLATIONAL RESEARCH

NRG-BR005: This phase II trial studies how well biopsy of the breast after chemotherapy works in predicting pathologic response in patients with stage II-IIIA breast cancer who are undergoing breast-conserving surgery. Tumor tissue collected from biopsy before surgery may help to check if chemotherapy destroyed the breast cancer cells and may be compared to the tumor removed during surgery to check if they are the same.

The purpose of this study is to look at tumor tissue collected from a biopsy done before breast surgery to check if the chemotherapy that patients received destroyed their breast cancer cells.

Learn more about the NRG-BR005 trial or contact the Reading Hospital Protocol Office at 484-628-8193.

Alliance-A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

The purpose of this research study is to examine lung cancer patients’ surgically removed tumors for certain genetic changes and to possibly refer these patients to a treatment study with drugs that may specifically target tumors that have these genetic changes.

Learn more about the Alliance-A151216 trial or contact the Reading Hospital Protocol Office at 484-628-8193.

CARIS/TCBIO-001-0710: The Caris Biorepository Research Protocol.

The Caris Biorepository is designed to collect and store medical record information and biospecimens such as blood and tissue. Research using biospecimens is an important way to try to understand human health and medical conditions, and to learn how to protect health and prevent, treat or cure conditions such as cancer, and perhaps other diseases as well.

Learn more about the The Caris Biorepository study or call the Reading Hospital Protocol Office at 484-628-8193.

OBSERVATIONAL - SURVEY STUDY

Palliative AssesSment Survey (PASS): History of Cancer Diagnosis (current or past). Treatment of Cancer with Chemotherapy, Radiation Therapy, Immunotherapy and/or Hormone Therapy

The purpose of this study is to assess the current quality of life issues and needs of our patients both during their cancer treatment and in the time beyond. To find the best palliative care options that would be most beneficial to the needs of our patients. To assess the effectiveness of the service we already offer and determine if there are any newer, better options to offer our patients based on their own opinions and experiences.

Learn more about the Palliative AssesSment Survery (PASS) or call the Phoenixville Hospital Clinical Research at 610-983-1811.